Targeting a key signaling pathway to fight aggressive prostate cancer
Suppression of Prostate Cancer
This study is looking at how a specific pathway in prostate cancer works, especially in cases that don't respond to usual treatments, and it's testing a new compound that could help slow down cancer growth, which might lead to better treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10684749 on NIH RePORTER |
What this research studies
This research investigates the role of the Wnt/β-catenin signaling pathway in aggressive prostate cancer, particularly in cases that are resistant to current treatments. The team is developing new molecules, specifically a compound called macrocycle 13, designed to inhibit this pathway and reduce prostate cancer cell growth. By testing this compound in models of castration-resistant prostate cancer, the research aims to uncover how it interacts with cancer cells and potentially leads to new treatment options. Patients may benefit from insights gained about the biology of prostate cancer and the development of targeted therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with aggressive prostate cancer, particularly those whose cancer has become resistant to standard treatments.
Not a fit: Patients with early-stage prostate cancer or those who do not have aggressive forms of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with aggressive prostate cancer that is resistant to existing therapies.
How similar studies have performed: Other research has shown promise in targeting the Wnt/β-catenin pathway for cancer treatment, indicating that this approach has potential based on previous findings.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Logan, Susan K. — New York University School of Medicine
- Study coordinator: Logan, Susan K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.